Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Emergex Vaccines Holding Ltd
Emergex Vaccines Holding Ltd
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Recruitment
Dr Athanasios Papadopoulos joins Emergex as Chief Medical Officer
Oxford-based biotechnology company has appointed a clinical bio-pathology specialist
Research & Development
Emergex secures R&D facility in Oxfordshire
English biotech company now has overall internal control of all its vaccine development programmes
Infection Control
Emergex to develop novel vaccines against viral diseases
The biotech will collaborate with the Oswaldo Cruz Foundation to develop the vaccines
Pharmaceutical
Emergex files patent in US for novel pandemic flu vaccine
The patent, ‘Reverse Peptide Vaccines’, covers the use of peptides derived from human influenza A
Manufacturing
Emergex receives Innovate UK Grant to progress flu vaccine
The biotechnology company, which is aiming to find a new approach to vaccine development, has received a grant to progress its development programme
Recruitment
Emergex Vaccines appoints new member to board of directors
Recruitment
Emergex builds its Finance Team with two new recruits
Subscribe now